OncoLink at ASTRO 2001: Sunday, November 4

Join OncoLink at the 43rd annual meeting of the American Society for Therapeutic Radiology and Oncology, where we are offering up-to-the-minute coverage.

OncoLink at ASTRO 2001 (Booth 2450)

Biclutamide ("Casodex") 150 mg as Adjuvant to Radiotherapy in Localized or Locally Advanced Prostate Cancer Presenter: C. Tyrrell Affiliation: Plymouth Oncology Centre, Plymouth, United Kingdom BackgroundBiclutamide (Casodex) is often used as adjuvant therapy in patients who have biochemical failure after definitve therapy. This is a study to evaluate...
Epidermal Growth Factor Receptor is a Predictor of Tumor Response in Locally Advanced Rectal Cancer Patients treated with Preoperative Radiotherapy Presenter: J.S. Kim Affiliation: Radiation Oncology, Hospital Vall d'Hebron, Barcelona, Spain Background Epidermal growth factor receptor (EGFR) is a member of the tyrosine kinase receptor family and is expressed in a variety of different cell...
Impact of TNM Stage on Survival and Disease Control in Adjuvant Rectal Cancer Pooled Analysis Presenter: L.L. Gunderson Affiliation: Institution: Oncology, Mayo Clinic, Rochester, MN BackgroundThis study attempts to evaluate the TMN staging and the MAC staging as predictors of outcome such as overall survival and patterns of failure for...
Opening Ribbon Cutting Ceremony at the 43rd Annual ASTRO Meeting imgCt) { thisPic = 0 } if (thisPic Slide Show of this morning's opening of the conference. previous next ...
Phase II Trial of Preoperative Chemoradiation with a Hyperfractionated RT Boost in Locally Advanced Rectal Cancer Presenter: H. Diratzouian Affiliation: Fox Chase Cancer Center, Philadelphia, PA Background Studies have reported a dose response relationship for preoperative radiation therapy. The Fox Chase group has previously reported the results of a phase...
Preliminary Results of a Radiation Therapy Oncology Group Trial (RTOG 9311), A Dose Escalation Study Using 3D Conformal Radiation Therapy in Patients with Inoperable Non-small Cell Lung Cancer Presenter: M.V. Graham Affiliation: Radiation Oncology, Phelps County Regional Medical Center, Rolla, MO Background Some investigators and clinicians are now questioning the utility of elective nodal irradiation in the treatment of lung cancer. ...
Preoperative Chemoradiation using Capecitabine in Locally Advanced Rectal Cancer Presenter: J.S. Kim Affiliation: Department of Therapeutic Radiology, Chungnam National University, Taejon, South Korea BackgroundStudies indicate that preoperative chemoradiation can result in tumor downstaging with increase resectability and...
Quantitation of the Early Effects of Radiation and Hormonal Therapy on Hemoglobin Levels in Men Treated for Prostate Cancer Presenter: J. Wilson Affiliation: University of Pennsylvania BackgroundAnemia has been shown to be a prognostic factor in head and neck and cervical cancer. However, unless hemoglobin falls to values Materials and Methods This is a...
Randomized Phase III Study of Amifostine in Patients Treated with Chemoradiation for Inoperable Stage II-III Non-Small Cell Lung Cancer (NSCLC) Presenter: R. Komaki Affiliation: Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX Background The radioprotective property of thiol-containing compounds has been well known for some time. Amifostine(WR-2721) ...
Randomized Study of Single Versus Fractionated Radiotherapy (RT) in the Palliation of Non-Small Cell Lung Cancer; NCIC CTG SC.15 Presenter: A. Bezjak Affiliation: Dept of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada Background In comparison to definitive radiation therapy, the optimal doses and fraction schedules for palliative treatments are less...
RTOG 9706: Initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with cisplatin followed by adjuvant MCV chemotherapy Presenter: M. P. Hagan Affiliation: Medical College of Virginia Background The standard of care for muscle invasive bladder cancer is radical cystectomy +/- adjuvant chemotherapy with or without radiation. However, there is much interest in...
Selective Bladder Preservation by Combined Modality Treatment of Invasive Bladder Cancer: 10 Year Outcome Presenter: W. U. Shipley Affiliation: Massachusetts General Hospital BackgroundThe standard of care for muscle invasive bladder cancer is radical cystectomy +/- adjuvant chemotherapy with or without radiation. However, to improve quality of life...
Survival Benefit for Early Initiation of Hormone Ablation Therapy in Patients who Fail Definitive XRT for Prostate Cancer (ACP) Presenter: T.C. Tenenholz Affiliation: Medical College of Virginia Background There is a dispute over the timing of starting hormones after biochemical failure. This study was initiated to determine when the benefits of hormonal ablation...